Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pregnancy-specific beta-1-glycoprotein 3 (PSG3)
- Target
- PSG3
- Molecular classification
- Other (member of the pregnancy-specific glycoprotein family, a subset of the immunoglobulin superfamily)
01
Overview
Pregnancy-specific beta-1-glycoprotein 3 (PSG3) is a member of the pregnancy-specific glycoprotein family, which are major secreted proteins produced by placental syncytiotrophoblasts and released into the maternal circulation during pregnancy. PSG3 is one of several closely related glycoproteins (PSG1-PSG11 in humans) within the immunoglobulin superfamily. They are primarily thought to play a role in promoting immune tolerance of the mother toward the fetus, supporting placental development, and modulating inflammation. PSG3 is not classically regarded as a druggable receptor, enzyme, transporter, or canonical immune checkpoint target, and no approved drugs are known to selectively target this molecule. Its major relevance clinically is as a biomarker for pregnancy status and potentially for abnormal pregnancy conditions when measured in maternal blood. PSG3 should not be confused with the scaffolding protein supramodule "PSG" (PDZ3-SH3-GK) found in postsynaptic proteins, as this is unrelated at the molecular, functional, and biological level.
- Other names
- PSG3PS-beta-G-3PSBG-3Pregnancy-specific glycoprotein 3Carcinoembryonic antigen SG5
02
Biological functions
Immune responseModulation of maternal immune tolerance during pregnancyFetal developmentOther
03
Disease associations
Other (Primarily involved in normal pregnancy; altered levels may be associated with pregnancy complications but not directly linked as a target in cancer or other major diseases)
04
Biomarkers
Pregnancy statusPossible marker for placental health and some pregnancy-related disorders
Beyond the preview
Go deeper on Pregnancy-specific beta-1-glycoprotein 3 (PSG3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pregnancy-specific beta-1-glycoprotein 3 (PSG3).